Latest News from GbS' Global Parent Company

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis

Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge

Choose Your Area Of Interest

Research Partners

The strength of our R & D pipeline has been the participation of world class researchers from 9 international universities over the past 7 years. Together, we have assembled the ultimate toolkit to create the future of medicine; AI technology, plant-based medicine, and hard sciences.

Development Partners

Translating new drug principles into real world medicines requires expertise in several disciplines. Our partners help make our dream of novel plant-inspired medicines a reality by providing expertise in cGMP-certified active ingredients and novel oral delivery methods.


Our Goal is to preserve the efficacy of plant-based medicines while reducing their complexity for standardization.

Our Strategy is to combine our proprietary PhAROS Drug Discovery Platform and High Throughput Screening of Cell and Animal Models of Specific Disease Processes to Create Rationally-Designed, Minimum Essential Mixtures.

Looking to learn more about Gb Sciences?

Learn about Gb Sciences' research developments, patents, and emerging drug discoveries by visiting our News Room.